95129c Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his base was raised to $602,500. Who knows how well he will do with bonuses and perks.

CEGE blew up today. The company ended a clinical trial of its prostate cancer vaccine GVAX because patients who were treated with the vaccine were dying more frequently than those only given a standard treatment.

That bit of bad news took the shares down to $.69 from a 52-week high of $4.67.

The market cap of Cell Genesys is only $62 million now, so Dr. Sherwin is doing a bit too well.

Douglas A. McIntyre

“The Next NVIDIA” Could Change Your Life

NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.

The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”

The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below

Check Your Email! “The Next NVIDIA” Report is Being Sent to Your Inbox Right Now

By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.